| Name | Title | Contact Details |
|---|---|---|
Shadi Hijjawi |
Associate Chief Medical Information Officer | Profile |
Matthew Snyder |
Senior Vice President, Chief Information Security and Privacy Officer | Profile |
Edward Smiley |
Director of Cyber Risk Management | Profile |
Cletis Earle |
Senior Vice President and Chief Iinformation Officer | Profile |
BioRealty, Inc. is a San Clemente, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Water Lens is an innovative company that is revolutionizing the $10B water testing industry. We have developed a system for real-time chemical analysis of water and other fluids, on location, for industries that use large amounts of water (e.g., oil and gas, agriculture, power generation, coal mining, and food processing).
Wherever you are, exhale Therapeutic Air® to immediately access the ancient wellness art of aromatherapy. Unlike topical oils or household diffusers, MONQ® is enhanced for convenience in the modern age. Experience the most direct form of aromatherapy with MONQ Personal Diffuser.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.
MediCall is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Pleasanton, CA. To find more information about MediCall, please visit www.medicall.us